Eton Pharmaceuticals Inc (NAS:ETON)

Q2 2026 Eton Pharmaceuticals Inc Earnings Call Transcript

Aug 13, 2026 / 08:30 PM GMT

Release Date Price: $40.72 (-2.07%)

Transcript 10-Q8-K

Key Points

Positve

Eton Pharmaceuticals Inc (ETON) achieved record second-quarter revenue of $37.6 million, a 99% year-over-year increase, driven by strong performance across its portfolio.
The company significantly expanded profitability, with adjusted EBITDA reaching $16.2 million (43% of revenue) in Q2 2026, up from $3.6 million (16% of revenue) in the prior year quarter.
The relaunch of Hemangiol exceeded expectations, with approximately 95% of patients transitioned to the new Eaton Cares model by the end of June, well ahead of the initial 3-4 month timeline.
Eton Pharmaceuticals Inc (ETON) expanded its pipeline and commercial portfolio through strategic acquisitions, including the licensing of ASN-001, a late-stage candidate for infantile hemangiomas with a potential patient population 2-3 times larger than Hemangiol.
The company raised its full-year 2026 revenue guidance to exceed $145 million (up from $120 million) and expects adjusted EBITDA margin to exceed 35%, reflecting strong operational leverage and a positive outlook.
Eton Pharmaceuticals Inc (ETON) received fast-track designation from the FDA for Amglidia, a potential first approved oral treatment for neonatal diabetes in the U.S., and plans to submit the NDA by the end of 2026.

Negative

Adjusted gross margin decreased to 73% in Q2 2026 from 75% in the prior year period, primarily due to higher Increlex sales outside the U.S., which generate a negative gross margin.
The company expects to incur significant R&D expenses related to the ASN-001 licensing payment ($3 million) and its bioavailability study (approximately $4 million over the next 12 months), which could pressure near-term profitability.
Eton Pharmaceuticals Inc (ETON) faces execution risks in launching new products, including the upcoming U.S. distribution of Impavito in late September and the ongoing development of ASN-001, which is not expected to launch until 2028.
The company's cash position stood at $26.8 million at the end of Q2 2026, which may limit its ability to pursue larger acquisitions without external financing, despite its stated ambition to expand its portfolio.
The company remains in a cumulative loss position for tax purposes, and while it may release its $22 million valuation allowance in the second half of 2026, this is contingent on continued execution against its forecast.
Eton Pharmaceuticals Inc (ETON) faces competitive and market risks in converting patients from off-label products to its approved therapies, particularly for Hemangiol and Galzin, where less than half of the eligible patient population has been converted.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ETON.OQ - Eton Pharmaceuticals Inc
Q2 2026 Eton Pharmaceuticals Inc Earnings Call
Aug 13, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon, and welcome to the Eaton Pharmaceuticals Second Quarter 2026 Financial Results Conference Call. At this time, all participants are in listen-only mode. Following the formal remarks, we will open the call up for your questions. Please be advised this call is being recorded at the company's request.

At this time, I'd like to turn the call over to David Krempa, Chief Business Officer at Eaton Pharmaceuticals. Please proceed.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator. Good afternoon, everyone, and welcome to Eaton's second

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.